NYSE · MTD
Mettler-Toledo International Inc.
$1,718.61+$20.14 (+1.19%)
Mettler-Toledo International Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.58% below the high.
Loading market information…
NASDAQ · TRNS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Transcat, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Transcat, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of $0.45. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Transcat, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Transcat, Inc. is a provider of accredited calibration and laboratory instrument services, and a value-added distributor of professional grade test, measurement, and control instrumentation. The company operates through two segments, Service and Distribution, and focuses on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceutical, biotechnology, and medical device businesses.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 |
|---|
| May 19, 2025 |
| $0.64-3.03% vs estimate |
| $77.13M+0.61% vs estimate |
| Q3 2025 | Jan 27, 2025 | $0.45+18.42% vs estimate | $66.75M-5.04% vs estimate |
|---|
| Q2 2025 | Oct 28, 2024 | $0.35-23.91% vs estimate | $67.83M-3.52% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,718.61+$20.14 (+1.19%)
Mettler-Toledo International Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.58% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$384.40-$0.72 (-0.19%)
Bio-Rad Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.99% below the high.
$17.93-$0.06 (-0.33%)
NeoGenomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.02% below the high.
$293.30+$7.30 (+2.55%)
UFP Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$10.39+$0.39 (+3.9%)
TIC Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.75% below the high.
$38.61$0.00 (0.0%)
BioLife Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.89% below the high.
$13.76-$0.25 (-1.78%)
QuidelOrtho Corporation’s quoted price sits in the lower half of its reported 52-week range, 61.33% below the high.
